Publication at First Faculty of Medicine, Second Faculty of Medicine |
2022
Abstract
The effectiveness of nintedanib in slowing the decline in lung function in patients with a progressive fibrotic (PF) phenotype of the interstitial lung process (IPP) was validated in the INBUILD clinical trial, published in 2019. While the concomitant use of nintedanib and immunosuppressants was limited in this study, the practice before deciding whether to replace nintedanib with immunosuppression or to add it to existing treatment is quite common.
To date, many studies have been published on the tolerability of combined immunosuppressive and antifibrotic therapy. The communication provides an overview of the experience with combined immunosuppressive and antifibrotic treatment in six patients with good tolerance.